# KayoThera

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kayothera

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.kayothera.com
- Total disclosed funding: $10M
- Latest round: Series A (Jul 13, 2023)
- Investors on record: 5

## About

Based in New Jersey, US, and founded in 2019 by its Vice-president, Mark Esposito, and scientific advisory board member Yibin Kang, KayoThera, Inc., operates as a biotechnology company that develops immuno- and targeted therapies to cure cancer. In March 2022, KayoThera, Inc. raised series A funding from Accelerator Life Science Partners, with participation from BioAdvance. New investors Pier 70 Ventures, and WRF Capital., and received an expanded financing in July 2023. As of 2023, Thong Q. Le acts as the President and CEO of the company.

KayoThera offers therapies to treat late-stage and metastatic cancers, including breast, lung, pancreatic, colorectal, brain, and kidney cancers.

The company intends to use the July 2023 funding to accelerate product development programs in diabetes and oncology.

## Funding rounds

- Series A, Jul 13, 2023, $6.5M — WRF Capital, BioAdvance, Accelerator Life Science Partners, Pier 70 Ventures
- Series A, Mar 11, 2022, $4M — BioAdvance, Accelerator Life Science Partners, 7G BioVentures

## Investors

- BioAdvance (https://capitalatlas.ai/funds/bioadvance) — Series A
- Accelerator Life Science Partners (https://capitalatlas.ai/funds/accelerator-life-science-partners) — Series A
- 7G BioVentures (https://capitalatlas.ai/funds/7g-bioventures) — Series A
- WRF Capital (https://capitalatlas.ai/funds/wrf-capital) — Series A
- Pier 70 Ventures (https://capitalatlas.ai/funds/pier-70-ventures) — Series A